Q-omics provides the consensus-scored TMEM119 profile across patient tissues and cancer cell-line models. TMEM119 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, TMEM119 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, TMEM119 RNA expression shows 24,689 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, THCA, and LSCC as cancer lineages where TMEM119 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM119 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM119 survival associations across molecular data types. TMEM119 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM119 RNA expression–survival associations across cancer types. High TMEM119 expression shows unfavorable associations in UVM, ACC and KIRP, but favorable associations in HNSC, UCS and LUAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for TMEM119 RNA expression.
This table summarizes TMEM119 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 7. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TMEM119. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM119 shows lower tumor expression in THCA, KICH, UCEC and LUSC and higher tumor expression in LIHC and HNSC. The THCA box plot shows higher TMEM119 RNA expression in normal versus tumor tissue (log2 FC = −2.211, t-test p < 0.001).
This table shows molecular features associated with TMEM119 in patient tissues and cancer cell lines. In patient samples, TMEM119 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM119 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BONE.
